2349 Stock Overview
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Jinghua Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥7.71 |
52 Week High | CN¥11.00 |
52 Week Low | CN¥5.88 |
Beta | 0.11 |
1 Month Change | -2.90% |
3 Month Change | -0.52% |
1 Year Change | -28.28% |
3 Year Change | 63.35% |
5 Year Change | 16.47% |
Change since IPO | 129.92% |
Recent News & Updates
Recent updates
Shareholder Returns
2349 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 4.2% | 0.8% | -0.4% |
1Y | -28.3% | -13.4% | -14.4% |
Return vs Industry: 002349 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 002349 underperformed the CN Market which returned -14.4% over the past year.
Price Volatility
2349 volatility | |
---|---|
2349 Average Weekly Movement | 6.8% |
Pharmaceuticals Industry Average Movement | 7.7% |
Market Average Movement | 8.8% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002349 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002349's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1957 | 1,641 | Yunzhong Zhou | www.jinghuapharm.com |
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd.
Jinghua Pharmaceutical Group Co., Ltd. Fundamentals Summary
2349 fundamental statistics | |
---|---|
Market cap | CN¥6.28b |
Earnings (TTM) | CN¥247.70m |
Revenue (TTM) | CN¥1.51b |
25.3x
P/E Ratio4.2x
P/S RatioIs 2349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2349 income statement (TTM) | |
---|---|
Revenue | CN¥1.51b |
Cost of Revenue | CN¥775.64m |
Gross Profit | CN¥736.11m |
Other Expenses | CN¥488.41m |
Earnings | CN¥247.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | 0.30 |
Gross Margin | 48.69% |
Net Profit Margin | 16.38% |
Debt/Equity Ratio | 0.8% |
How did 2349 perform over the long term?
See historical performance and comparison